A cancer vaccine seems promising and requires an investment

A study published by the “Nature” magazine in February confirms the possibility of a new vaccine dedicated to preventing the return of pancreatic cancer. The experiment was narrow as it was limited to 16 patients, but it caused a feeling that was usually not associated with this cruel disease, which is hope. It is known that pancreatic cancer kills the kill. So, if the researchers provide data indicating that a vaccine is prepared for each individual case, it can keep cancer under control for years, it is worth paying attention, even if the results include some people. It must also be an invitation to zeal. The progress has always been very slow for this group of patients and their families, and they deserve better options. The only way to achieve this is to continue investing in the kind of basic research, which through decades of careful work becomes a basis for supernatural successes. Even with a slow and fixed progress over the past decade to improve survival rates, only 13% of those diagnosed with pancreatic cancer remained alive after five years. This cancer is therefore the third most deadliest types of cancer in the United States, to lung and colon cancer. A quiet, rapid illness was to find very difficult treatments, as patients usually do not suffer from symptoms and there are no simple tests for the disease. By the time of his discovery, it usually spread to the nearby organs, so that the possibility of the best treatments, if existed, becomes unlikely. This new round data is devoted to the vaccine provided types of mRNA, built on the cofid vaccines, and contains a long list of patient proteins. The idea here is to learn the immune system to get to know and destroy the parts of the crop when it finds it. ‘Our modern’ is aimed at launching a vaccine in the skin cancer in 2027. This concept may seem simple, but before the data starts to appear from this small experience, only little expected the immune system to be directed against pancreatic cancer. Vaccines usually work better if the crop is full of transformations, as is the case in the melanoma, where an MRNA vaccine of ‘modern’ and ‘Merck’ shows promising results. This is what makes the previous information of this study very amazing: The vaccine has strengthened the immune response to this strong crop of half of the participants and they are 16 patients. But the researchers did not know if the cancer -resistant immune cells, which would remain the T -cells generated by the vaccine – and even if they left, will they continue to do their job? Promising results now we know that these immune cells can last for some people and can last for a lifetime. It seems to keep the functions that believe the repetition of the disease, says Vinod Balshandran, the surgeon of pancreatic cancer at the Memorial Sloan Kiting Center for Cancer who led the study. Only two cancer of the eight patients who showed a strong response to T -cells returned. (But the disease returned to seven of eight patients whose immune system did not respond to the vaccine). The Swiss “Roche” determines the patients with lung cancer with artificial intelligence of this approach, as the doctors need a sample of the patient’s tumor to do the designated vaccine, but only about five patients with pancreatic cancer may undergo the necessary surgery. Barra Brigham, Jeddah, discovered that she had pancreatic cancer in September 2020, and that she was one of the lucky ones who responded to the vaccine for years. Routine tests have not appeared any sign of cancer since she was the treatment of vaccine assigned to her and completed chemotherapy in the fall of 2021. It could attend a number of her grandchildren and one of them, as well as attending the birth of her eighth grandson in December. Brigham told me that it was “events I didn’t think I would have been present to bring them.” Women are still under control every six months in search of cancer evidence, but she has achieved some goals on her list of life. She has always wanted to be on a speed on the Rhine to visit her family’s birthplace in Germany, and she believes she could do it in 2026. She says, “I make my fingers and say, I will do it in the end.” Would it be better than chemotherapy? Of course, there are many other questions that need to be answered before the vaccine is ready to use. Patients are currently registered in a larger study that will help researchers a better understanding of the immune response mechanism. The decisive thing here is that this experiment should tell us whether the vaccine performs a better function than traditional chemotherapy in preventing cancer return. But this initial success against this stubborn crop has a greater effect on the use of vaccines (MRNA) dedicated to the target of other crops that have so far been resistant to other types of immunotherapy, as he says in Shandran. “Pfizer” acquires “Cancer medicine ‘sigign with $ 43 billion. It helps researchers understand how vaccines are used to treat other general crops that have so far been resistant to other types of immunotherapy. We need to develop a better scheme to design cancer vaccines that work as expected. If you pay this work forward with the speed it deserves, it will require coordinated efforts and large investments of government, biotechnology businesses and charities. However, it is difficult not to worry about the loss of momentum due to the current environment in the national health institutions, which has contributed to financeing the basic work to develop the vaccine, and to note the basic work for the development of technology (MRNA). How unhappy will be, this cancer has stolen many families, and if there is a possibility to benefit more people, we must move as soon as possible to achieve it.